Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's DiseaseStephen Salloway, H. Robert Brashear, Reisa A. Sperling et al.|New England Journal of Medicine|2014Cited by 2k
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable WorkgroupReisa A. Sperling, Rachel Schindler, Clifford R. Jack et al.|Alzheimer s & Dementia|2011Cited by 830
Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysisReisa A. Sperling, Michael Grundman, Stephen Salloway et al.|The Lancet Neurology|2012Cited by 510
Amyloid-β <sup>11</sup> C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trialsEnchi Liu, Arthur Spirling, Mark E. Schmidt et al.|Neurology|2015Cited by 152
Designing drug trials for Alzheimer's disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task ForceBruno Vellas, María C. Carrillo, Cristina Sampaio et al.|Alzheimer s & Dementia|2013Cited by 145